This content is from: Home

Will the Glivec decision slow innovation?

In the aftermath of the Glivec decision, multinational pharmaceutical companies are concerned about the status of the patent protection in India and are issuing dire warnings about impediments to drug development. Is there really cause for worry?

Get Free Access to read more …

To read the full article, activate your free trial.

Get Free Access
  • Unlimited articles for one week
  • No commitments; no payment details required
  • Featuring IP strategy, copyright, patents, trademark and more!

Are you a Managing IP subscriber? Simply login here.